Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review
Executive Summary
Generic perphenazine is recommended as first-line treatment for schizophrenia by Consumer Reports Best Buy Drugs based on a comparison of efficacy, adverse events and cost-effectiveness of 13 antipsychotic drugs
You may also be interested in...
CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program
CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program
Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports
Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: